HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

about

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 Role of raltegravir in the management of HIV-1 infection.

P2860

Q35083423-D4131977-362A-4763-AB99-BA9EC508E223 Q35557318-F74A4944-6C75-483E-AD47-7923214D1522

P2860

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

Item

http://www.wikidata.org/entity/Q58391480

description

article

@en

im Februar 2011 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2011

@uk

name

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

@en

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

@nl

type

Item

label

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

@en

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

@nl

prefLabel

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

@en

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

@nl

P1476

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

@en

P2093

Daniela Francisci

http://www.w3.org/2001/XMLSchema#string

Franco Baldelli

http://www.w3.org/2001/XMLSchema#string

Giulia Masini

http://www.w3.org/2001/XMLSchema#string

Laura Martinelli

http://www.w3.org/2001/XMLSchema#string

Liliana E. Weimer

http://www.w3.org/2001/XMLSchema#string

Marco Floridia

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.

Antiretroviral drug resistance in human immunodeficiency virus type 2.

Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

Raltegravir treatment response in an HIV-2 infected patient: a case report.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11539940-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P50

Maurizio Zazzi

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21344955

http://www.w3.org/2001/XMLSchema#string

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

about

P2860

P2860

HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698